Aim Immunotech Inc (AIM) Stock Price, Quote & News

Company Profile

AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon produ...

Industry: Biotechnology

Sector: Healthcare

Phone: 352 448 7797

Fax: 352 480 4620

Website: aimimmuno.com

Address:

2117 SW Highway 484, Ocala, United States

Teleboy May. 15 at 8:55 PM

$AIM 10Q https://s3.amazonaws.com/sec.irpass.cc/2265/0001493152-26-023750.htm

2 · Reply

TheLionofwallstreet May. 15 at 8:04 PM

$AIM expensive lesson. Maybe I load more to go out with a bang. Either the nail in the coffin or the key to set me free.

1 · Reply

DrInvest26 May. 15 at 7:05 PM

$AIM the stock is moving slightly upwards. Is this a sign of end of times 😂

0 · Reply

igor9040 May. 15 at 2:50 PM

$AIM loading up

0 · Reply

WallStreetIsNotEasy May. 15 at 2:04 PM

$AIM easy money down here even if they split again LOAD THE F UP!!

1 · Reply

elon_musk22 May. 15 at 2:01 PM

$AIM now bankrupt thanks a lot bull mar your naked short lies bankrupt investors you were the #1 pumper for 10 yrs loser

0 · Reply

goossest May. 15 at 1:59 PM

$AIM Ebola outbreak CBS News : A new Ebola outbreak in a remote Congo province has recorded 65 deaths so far and has 246 suspected cases, Africa CDC says. https://www.cbsnews.com/news/ebola-congo-dozens-dead-hundreds-more-possible-cases/?ftag=CNM-00-10aab7e&linkId=942985666

0 · Reply

jonjonson1234 May. 15 at 1:35 PM

$AIM I'm guess that the company will wait until the end of trading today to release the 10-Q. Both in government and in the corporate world, people like to release bad news after trading ends on a Friday.

1 · Reply

PhantaJuicy May. 15 at 1:15 PM

$AIM Wall Street Journal says AIM will report Q1 earnings on 05/15/2026.

0 · Reply

ultimatebastos May. 15 at 7:00 AM

$AIM Naked shorting

0 · Reply

AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer

May 8, 2026, 8:40 AM EDT - 7 days ago

AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds

May 7, 2026, 8:23 AM EDT - 8 days ago

AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential

ORR

Apr 16, 2026, 4:00 PM EDT - 4 weeks ago

AIM ImmunoTech Transcript: Virtual Investor Closing Bell

2026-04-16T13:59:51.000Z - 4 weeks ago

AIM ImmunoTech highlights accelerating momentum in pancreatic cancer program

Apr 13, 2026, 6:00 PM EDT - 4 weeks ago

AIM ImmunoTech Provides Routine Update on Annual Filings

2026-03-20T14:55:28.000Z - 2 months ago

Biotech Alert: Searches spiking for these stocks today

2026-03-18T13:47:09.000Z - 2 months ago

Why Is AIM ImmunoTech Stock (AIM) Up Today?

2026-03-18T12:51:46.000Z - 2 months ago

AIM announces approval of patent for Ampligen in Japan

Mar 18, 2026, 8:36 AM EDT - 2 months ago

AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors

Mar 6, 2026, 7:00 PM EST - 2 months ago

AIM ImmunoTech Announces Closing of its Rights Offering

2026-03-04T15:25:35.000Z - 2 months ago

Biotech Alert: Searches spiking for these stocks today

2026-03-04T14:05:33.000Z - 2 months ago

AIM ImmunoTech announces preliminary results of rights offering

2026-03-02T14:10:12.000Z - 2 months ago

AIM ImmunoTech signs agreement for planning of Phase 3 trial of Ampligen

TMO

Mar 2, 2026, 9:00 AM EST - 2 months ago

AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer

2026-02-27T14:11:50.000Z - 2 months ago

AIM ImmunoTech reminds stockholders of expiration date for rights offering

Feb 27, 2026, 9:00 AM EST - 2 months ago

AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering

2026-02-25T14:19:06.000Z - 2 months ago

AIM ImmunoTech extends subscription period of rights offering

2026-02-23T14:07:05.000Z - 2 months ago

AIM announces planned milestones in Phase 2 trial of Ampligen, Durvalumab

AZN

Feb 23, 2026, 8:55 AM EST - 2 months ago

AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the Treatment of Metastatic Pancreatic Cancer

Feb 19, 2026, 4:00 PM EST - 3 months ago

AIM ImmunoTech Transcript: Virtual Investor Closing Bell

Feb 12, 2026, 4:35 PM EST - 3 months ago

CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering

Feb 11, 2026, 1:40 PM EST - 3 months ago

AIM ImmunoTech Transcript: Corporate Connect Webinar Series

2026-02-11T13:35:13.000Z - 3 months ago

AIM ImmunoTech announces commencement of rights offering

Feb 11, 2026, 8:30 AM EST - 3 months ago

AIM ImmunoTech Announces Commencement of Rights Offering

2026-02-09T16:55:26.000Z - 3 months ago

Biotech Alert: Searches spiking for these stocks today

2026-02-06T16:45:33.000Z - 3 months ago

Biotech Alert: Searches spiking for these stocks today

Feb 6, 2026, 8:55 AM EST - 3 months ago

AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

2026-02-05T14:18:08.000Z - 3 months ago

Why Is AIM ImmunoTech Stock Up Today?

2026-02-05T13:45:30.000Z - 3 months ago

AIM ImmunoTech reports data in year-end update from Phase 2 trial of Ampligen

Feb 5, 2026, 8:40 AM EST - 3 months ago

AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

2026-01-23T18:40:14.000Z - 4 months ago

AIM ImmunoTech Inc trading resumes

Jan 23, 2026, 1:22 PM EST - 4 months ago

AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering

2026-01-23T17:30:16.000Z - 4 months ago

AIM ImmunoTech Inc trading halted, news pending

Dec 16, 2025, 11:00 AM EST - 5 months ago

AIM ImmunoTech Transcript: AGM 2025

Dec 4, 2025, 4:00 PM EST - 5 months ago

AIM ImmunoTech Transcript: Virtual Investor Closing Bell Series

Dec 1, 2025, 8:55 AM EST - 5 months ago

AIM ImmunoTech to Participate in Live ‘Fireside' Chat on Virtual Investor Closing Bell Series

Nov 18, 2025, 8:55 AM EST - 6 months ago

AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program

Nov 10, 2025, 8:55 AM EST - 6 months ago

AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen's Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer

Nov 4, 2025, 9:05 AM EST - 6 months ago

AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

Oct 20, 2025, 9:15 AM EDT - 7 months ago

AIM ImmunoTech to Attend the 2025 Maxim Growth Summit

Sep 25, 2025, 8:45 AM EDT - 8 months ago

AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors

Sep 4, 2025, 11:00 AM EDT - 9 months ago

AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland

Aug 21, 2025, 9:00 AM EDT - 9 months ago

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

Aug 15, 2025, 9:00 AM EDT - 9 months ago

AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 8:55 AM EDT - 9 months ago

AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 6, 2025, 9:00 AM EDT - 10 months ago

AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025)

Aug 4, 2025, 9:00 AM EDT - 10 months ago

AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval

Jul 2, 2025, 8:55 AM EDT - 11 months ago

AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies

Jun 20, 2025, 4:15 PM EDT - 11 months ago

AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements

Jun 17, 2025, 8:55 AM EDT - 11 months ago

AIM ImmunoTech Resumes Trading on NYSE American

Jun 12, 2025, 8:30 AM EDT - 1 year ago

AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®

Jun 12, 2025, 8:00 AM EDT - 1 year ago

AIM ImmunoTech Announces NYSE American Removal of Trading Suspension

Jun 11, 2025, 4:15 PM EDT - 1 year ago

AIM ImmunoTech Announces 1-for-100 Reverse Stock Split

May 8, 2025, 8:45 AM EDT - 1 year ago

AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists

Apr 7, 2025, 1:26 PM EDT - 1 year ago

AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market

Apr 4, 2025, 4:45 PM EDT - 1 year ago

AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal

Apr 4, 2025, 4:05 PM EDT - 1 year ago

NYSE American to Commence Delisting Proceedings Against AIM ImmunoTech Inc. (AIM)

Apr 1, 2025, 8:30 AM EDT - 1 year ago

AIM ImmunoTech Earnings Call Transcript: Q4 2024

Mar 11, 2025, 8:45 AM EDT - 1 year ago

AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 28, 2025, 8:45 AM EST - 1 year ago

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

Feb 26, 2025, 1:20 PM EST - 1 year ago

AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance

Feb 26, 2025, 8:30 AM EST - 1 year ago

AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director

Feb 25, 2025, 8:30 AM EST - 1 year ago

AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer

Feb 11, 2025, 8:45 AM EST - 1 year ago

AIM ImmunoTech Releases Virtual Investor “What This Means Segment”

Feb 11, 2025, 8:30 AM EST - 1 year ago

AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024

Feb 7, 2025, 8:50 AM EST - 1 year ago

AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM's Ampligen® and AstraZeneca's FluMist® to address the recent avian influenza outbreaks

Jan 23, 2025, 8:50 AM EST - 1 year ago

AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions

Jan 22, 2025, 8:30 AM EST - 1 year ago

AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS

Jan 15, 2025, 9:05 AM EST - 1 year ago

AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones

Dec 17, 2024, 4:45 PM EST - 1 year ago

AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

Dec 17, 2024, 3:10 PM EST - 1 year ago

AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting

Dec 16, 2024, 8:00 AM EST - 1 year ago

AIM ImmunoTech Reminds Shareholders to Vote “FOR” All Four Incumbent Board Members on the WHITE Universal Proxy Card

Teleboy May. 15 at 8:55 PM

$AIM 10Q https://s3.amazonaws.com/sec.irpass.cc/2265/0001493152-26-023750.htm

2 · Reply

TheLionofwallstreet May. 15 at 8:04 PM

$AIM expensive lesson. Maybe I load more to go out with a bang. Either the nail in the coffin or the key to set me free.

1 · Reply

DrInvest26 May. 15 at 7:05 PM

$AIM the stock is moving slightly upwards. Is this a sign of end of times 😂

0 · Reply

igor9040 May. 15 at 2:50 PM

$AIM loading up

0 · Reply

WallStreetIsNotEasy May. 15 at 2:04 PM

$AIM easy money down here even if they split again LOAD THE F UP!!

1 · Reply

elon_musk22 May. 15 at 2:01 PM

$AIM now bankrupt thanks a lot bull mar your naked short lies bankrupt investors you were the #1 pumper for 10 yrs loser

0 · Reply

goossest May. 15 at 1:59 PM

0 · Reply

jonjonson1234 May. 15 at 1:35 PM

1 · Reply

PhantaJuicy May. 15 at 1:15 PM

$AIM Wall Street Journal says AIM will report Q1 earnings on 05/15/2026.

0 · Reply

ultimatebastos May. 15 at 7:00 AM

$AIM Naked shorting

0 · Reply

Packmentality May. 14 at 5:54 PM

$AIM Endless promise of their product over many years… Will we ever learn why some group of people want this dead? Asking for a friend.

1 · Reply

Teleboy May. 14 at 1:50 PM

$AIM DURIPANC milestones: June 1st mid year report (4-6 weeks when he spoke later in the video); anticipate enrollment completion shortly afterwards; analysis of data should begin at the end of this year, and analysis of overall survival should begin in mid-year 2027.

1 · Reply

Teleboy May. 14 at 1:45 PM

$AIM Professor van Eijck speaks from 11:00 minutes to about 17:30 minutes. He is worth listening to. There is a transcript, which does make things easier. There is more after that, but at 22:20 or so Professor van Eijck talks about one of the key points regarding treatment which is that the quality of life of the patients is good, and that Ampligen needs to be integrated into the complete treatment protocol right from the beginning. That often gets raised in pancreatic cancer treatment as living longer with an awful quality of life is not much benefit in many cases.

0 · Reply

Teleboy May. 14 at 1:32 PM

$AIM Tom speaks for a while but the key bit is from circa 7:30 to 10:00 minutes in where he specifically addresses the plan regarding pancreatic cancer.

0 · Reply

Teleboy May. 14 at 1:28 PM

$AIM Tom stated in today's video they are aiming to have an update on the Astra-Zeneca sponsored DURIPANC trial out on June 1st.

0 · Reply

focafoca99 May. 14 at 1:21 PM

$AIM featured a virtual investor KOL segment spotlighting Ampligen breakthrough data in pancreatic cancer. https://www.rapidticker.com/news/aim-aim-immunotech-posts-virtual-investor-b85f3a

0 · Reply

Teleboy May. 14 at 1:12 PM

$AIM Key data from the Dutch pancreatic cancer study: 2/2 Based upon stratification for immune marker CA 19-9 less than 1000, PFS of 13.1 months compared to 8.6 months for historical controls, for an improvement of 4.5 months in PFS Based upon stratification for immune marker CA 19-9 less than 1000, OS of 24.1 months compared to 12.5 months for historical controls, for an improvement of 11.6 months in OS Clinical experience to date in both the NPP and DURIPANC suggest consistent improvement in Quality of Life

0 · Reply

Teleboy May. 14 at 1:11 PM

$AIM Key data from the Dutch pancreatic cancer study: 1/2 Progression-Free Survival (“PFS”) of 12.6 months compared to 8.6 months for historical controls, for an improvement of 4 months in PFS Overall Survival (“OS”) of 19.7 months compared to 12.5 months for historical controls, for an improvement of 7.2 months in OS Based upon stratification for immune marker Neutrophil/Lymphocyte ratios less than 4.5, PFS of 17.7 months compared to 8.6 months for historical controls, for an improvement of 9.1 months in PFS Based upon stratification for immune marker Neutrophil/Lymphocyte ratios less than 4.5, OS of 34.8 months compared to 12.5 months for historical controls, for an improvement of 22.3 months in OS

0 · Reply

Teleboy May. 14 at 1:08 PM

$AIM AIM has updated the Pancreatic Cancer data and their presentation (see slides 12-14 for pancreatic cancer data) https://d2ghdaxqb194v2.cloudfront.net/2265/199296.pdf https://aimimmuno.com/aim-immunotech-posts-virtual-investor-key-opinion-leader-segment-spotlighting-ampligen-breakthrough-data-in-pancreatic-cancer/

0 · Reply

Teleboy May. 14 at 1:06 PM

$AIM Prof. Dr. van Eijck, pancreatic cancer expert, examines Ampligen. This is via AIM, but his work is independent. https://virtualinvestorco.com/aim/

0 · Reply

keywestbitcoin May. 14 at 11:26 AM

$AIM i think with pop up from this .27 level, easy trade to .38 - .42, maybe!

0 · Reply

Dunqito May. 14 at 7:47 AM

$AIM hey geniuses, The exchange delists a stock, typically after filing a Form 25 with the SEC, which indicates the removal of the stock from its listings. The SEC oversees the process but does not directly delist stocks itself. Get a

1 · Reply

Market Cap	2.10M
Revenue (ttm)	90,000.00
Net Income (ttm)	-13.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-15,511.11%
Debt to Equity Ratio	-0.10

Volume	720,900
Avg Vol	4,416,838
Day's Range	N/A - N/A
Shares Out	8.15M
Stochastic %K	3%
Beta	1.24
Analysts	Sell
Price Target	$14.00